Malaria Vaccine Trials Going Well for GSK
Oct. 19--GlaxoSmithKline got more good news about its malaria vaccine Tuesday.
Results published online by the New England Journal of Medicine show that the vaccine has provided significant protection to young African children.
Earlier trials involving the vaccine -- called RTS, S -- had focused more on safety than effectiveness.
The results are from a phase-three trial, one of the final stages the vaccine must go through before GSK files to get the drug approved by regulators.
GSK, which is based in London but has its North American headquarters in Research Triangle Park, has spent hundreds of millions of dollars developing a malaria vaccine over the past two decades.
It is one of a number of pharmaceutical companies that have shifted their focus to vaccines in recent years. Two years ago, GSK opened a state-of-the-art vaccine packaging plant west of Philadelphia.
The company, which employs about 4,000 people in RTP, reports third-quarter earnings Oct. 26.
Posted: October 2011